Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
1. Metsera received an unsolicited acquisition proposal from Novo Nordisk. 2. Novo Nordisk offers $56.50 per share versus Pfizer's $47.50. 3. Pfizer considers Novo's offer as reckless and potentially illegal. 4. Metsera's Board prefers Pfizer's acquisition certainty over risks from Novo's proposal. 5. MTSR stock rose 21.03% amid acquisition news.